Novo Nordisk has launched its Wegovy weight-loss pill in the US at lower prices than injections. The once-daily pill is the first GLP-1 tablet approved and targets appetite suppression. Self-pay patients can access starting doses for $149 a month, far below injectable costs. The drug aims to appeal to patients seeking needle-free, affordable treatment options. Novo hopes the pill will regain market share lost to rivals like Eli Lilly. Shares rose after the launch, despite long-term competitive pressure. The pill is available at major pharmacies and telehealth platforms nationwide. Approval has so far been limited to the US, with UK regulators still reviewing the drug.
Novo Nordisk Launches Wegovy Pill in US, Intensifying Weight-Loss Drug Price War
OMN AI
This article was created with the assistance of OMN AI, the AI-powered editorial platform developed by OMN Group. Every article is reviewed, fact-checked, and approved by a human journalist before publication to ensure accuracy and editorial quality. Learn more at https://omngroup.com
